Read by QxMD icon Read

High grade non muscle invasive bladder cancer

Raffaella Santi, Tommaso Cai, Stefania Nobili, Ilaria Camilla Galli, Andrea Amorosi, Eva Comperat, Gabriella Nesi
The current WHO/ISUP classification and grading system subdivides urothelial tumours into prognostically distinct categories. Understanding the molecular pathways involved in bladder cancer development can improve patient stratification and management. This study aims to investigate the relationship between Snail, Slug and E-cadherin expressions and clinico-pathological features of non-muscle invasive bladder carcinoma (NMIBC). All patients attending the same urological centre from January to May 2002, who were pathologically diagnosed with NMIBC, were enrolled in this longitudinal cohort study...
March 10, 2018: Virchows Archiv: An International Journal of Pathology
Marcus George Kwesi Cumberbatch, Beat Foerster, James W F Catto, Ashish M Kamat, Wassim Kassouf, Ibrahim Jubber, Shahrokh F Shariat, Richard J Sylvester, Paolo Gontero
CONTEXT: Initial treatment for most bladder cancers (BCs) involves transurethral resection (TUR) or tumours. Often more cancer is found after the initial treatment in around half of patients, requiring a second resection. Repeat transurethral resection (reTUR) is recommended for high-risk, non-muscle-invasive bladder cancer (NMIBC) to remove any residual disease and improve cancer outcomes. OBJECTIVE: To systematically review the practice and therapeutic benefit of an early reTUR for high-risk NMIBC...
March 6, 2018: European Urology
Tarek Aboushousha, Olfat Hammam, Noha Helal, Samir El Dahshan
Objective: This study aimed to investigate the expression of cyclin D1 and hnRNP-K in relation to the pathological findings in bladder cancer including the type, grade, muscle invasion and bilharzial association. Methods: We studied the immunoexpression; as regard the percentage, intensity and score of both cyclin D1 and hnRNP-K in different bladder lesions including 10 cases of cystitis; 10 cases of carcinoma insitu (CIS), 20 cases of Squamous cell carcinoma (SCC) and 66 cases of urothelial carcinoma (UC)...
February 26, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
Junfeng Zhang, Longsheng Wang, Shiyu Mao, Mengnan Liu, Wentao Zhang, Ziwei Zhang, Yadong Guo, Bisheng Huang, Yang Yan, Yong Huang, Xudong Yao
PURPOSE: Transurethral resection of bladder tumor (TURBT) using a wire loop is considered the gold standard for staging and treating non-muscle invasive bladder cancer (NMIBC). TURBT is associated with serious disadvantages that facilitate tumor recurrence. The present study evaluated the safety and efficacy of the bipolar button electrode for en bloc resection of NMIBC. METHODS: From January 2013 to July 2016, 82 consecutive patients newly diagnosed with NMIBC received transurethral en bloc resection with bipolar button electrode...
February 24, 2018: International Urology and Nephrology
Roberto Giulianelli, Barbara Cristina Gentile, Gabriella Mirabile, Luca Albanesi, Paola Tariciotti, Giorgio Rizzo, Maurizio Buscarini, Mauro Vermiglio
INTRODUCTION: Understaging after initial transurethral resection is common in patients with high-risk non muscle infiltrating bladder cancer (NMIBC) and can delay accurate diagnosis and definitive treatment. The rate of upstaging from T1 to T2 disease after repeated transurethral resection ranges from 0 to 28%, although the rate of upstaging may be even higher up to 49% when muscularis propria is absent in the first specimen. A restaging classic transurethral resection of bladder tumour (re-cTURBT) is the better predictor of early stage progression...
December 31, 2017: Archivio Italiano di Urologia, Andrologia
Wolfgang Otto, Bas Wg van Rhijn, Johannes Breyer, Simone Bertz, Markus Eckstein, Roman Mayr, Eva M Lausenmeyer, Stefan Denzinger, Maximilian Burger, Arndt Hartmann
OBJECTIVES: To investigate established prognostic factors and relatively new histopathological tumor characteristics including metric substage and lamina propria invasion patterns in a large series of T1 high-grade non-muscle-invasive bladder cancer. METHODS: Between 1989 and 2012, 322 patients with initial stage T1 high-grade bladder cancer underwent transurethral resection, followed by re-transurethral resection and a conservative approach with follow-up regime alone or instillation treatment...
February 22, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
Ashfaque A Memon, Stephen C Gilliver, Michael Borre, Jan Sundquist, Kristina Sundquist, Ebba Nexo, Boe S Sorensen
The role of soluble human epidermal growth factor receptor (sHER3) in bladder cancer remains unclear. In the present study, an ELISA was developed for the quantification of sHER3 and its role was investigated in patients with bladder cancer (n=82) followed for 10 years. Furthermore, the effects of sHER3 on bladder cancer cell growth and migration were also investigated. The results demonstrated that plasma sHER3 levels were significantly higher in non-invasive tumours (Ta) compared with muscle-invasive tumours (T2-T4)...
February 2018: Oncology Letters
Francesco Pierconti, Esther Diana Rossi, Patrizia Straccia, Guido Fadda, Luigi Maria Larocca, Pier Francesco Bassi, Emilio Sacco, Giovanni Schinzari
BACKGROUND: Chemohyperthermia (C-HT) or electromotive drug administration (EMDA) are alternative therapies to radical cystectomy in patients with non-muscle-invasive bladder cancer who do not respond to intravesical therapy with bacille Calmette-Guérin. METHODS: The authors investigated a group of 87 patients with a diagnosis of high-grade non-muscle-invasive bladder carcinoma or carcinoma in situ. Of these, 45 patients received EMDA of mitomycin (EMDA/MMC) and 42 patients were treated with C-HT and mitomycin therapy (C-HT/MMC)...
January 23, 2018: Cancer Cytopathology
Malte W Vetterlein, Julia Roschinski, Philipp Gild, Phillip Marks, Armin Soave, Ousman Doh, Hendrik Isbarn, Wolfgang Höppner, Walter Wagner, Shahrokh F Shariat, Maurizio Brausi, Franziska Büscheck, Guido Sauter, Margit Fisch, Michael Rink
Background: The identification of protein biomarkers to guide treatment decisions regarding adjuvant therapies for high-risk non-muscle-invasive bladder cancer (NMIBC) has been of increasing interest. Evidence of the impact of tumor suppressor gene product p53 and cell proliferation marker Ki-67 on oncologic outcomes in bladder cancer patients at highest risk of recurrence and progression is partially contradictory. We sought to mirror contemporary expression patterns of p53 and Ki-67 in a select cohort of patients with pT1 bladder cancer...
December 2017: Translational Andrology and Urology
Piotr Zapała, Bartosz Dybowski, Sławomir Poletajew, Łukasz Białek, Andrzej Niewczas, Piotr Radziszewski
BACKGROUND: Indications for restaging transurethral resection of the bladder tumor (reTURBT) in patients with non-muscle-invasive bladder cancer (NMIBC) remain controversial. This study was aimed at evaluation of clinical value and safety of reTURBT in different clinical indications. METHODS: This is a retrospective analysis of consecutive 141 patients who underwent TURBT followed by reTURBT in years 2011-2015 in a single department. Pathological results and surgical complications were analyzed in the whole study cohort and stratified by clinical stage (Ta, T1, Tx (no muscle in the specimen)) and grade (low-grade (LG), high-grade (HG)) of bladder cancer diagnosed at primary TURBT...
January 15, 2018: World Journal of Surgical Oncology
S Poletajew, R Biernacki, P Buraczynski, J Chojnacki, S Czarniecki, D Gajewska, T Pohaba, J Sondka-Migdalska, M Skrzypczyk, T Suchojad, D Wojtkowiak, B Zaforemski, L Zapala, A Zemla, P Radziszewski
Adjuvant diagnostic and therapeutic procedures are available to reduce the risk of recurrence or progression in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, their indications and efficacy remain a matter of debate. The aim of this study was to analyze therapeutic decisions in patients with primary high-risk NMIBC and to analyze the adherence to clinical guidelines in this field.545 consecutive patients, aged a median of 70.3 years, diagnosed with primary high-risk NMIBC in thirteen urological institutions, were enrolled into this retrospective study...
2018: Neoplasma
Zahava Vadasz, Jacob Rubinstein, Jacob Bejar, Hilla Sheffer, Sarel Halachmi
OBJECTIVE: A highly sensitive and specific urine marker for the detection of recurrent urothelial cancer and for screening healthy population or people at risk for urothelial cancer has not been found yet. As urine cytology is not sensitive enough, patients with non-muscle-invasive bladder cancer need lifelong follow-up involving multiple invasive cystoscopies. Our aims of study were to examine the expression of semaphorin 3A in urothelial cancer patients and to evaluate semaphorin 3A as a potential marker for urothelial cancer...
December 26, 2017: Urologic Oncology
Guang-Qian Xiao, Mary M Barrett, Qi Yang, Pamela D Unger
Muscle invasive bladder cancer, an aggressive disease with heterogeneous molecular profiles, has recently been subclassified into three major molecular subtypes -basal, luminal and "p53-like" urothelial carcinomas (UCas), which bear prognostic and therapeutic implication. Similar to breast cancer, basal and luminal subtype UCas are designated by basal (CK5/14) and luminal (CK20) markers. The "p53-like" subtype presents with wild-type p53 gene with upregulated p53 pathways and is implicated in chemoresistance...
December 16, 2017: Pathology Oncology Research: POR
Owen T M Chan, Hideki Furuya, Ian Pagano, Yoshiko Shimizu, Kanani Hokutan, Lars Dyrskjøt, Jørgen Bjerggaard Jensen, Per-Uno Malmstrom, Ulrika Segersten, Filip Janku, Charles J Rosser
Background: We previously reported an accurate urine-based bladder cancer (BCa)-associated diagnostic signature that can be used to non-invasively detect BCa. In this study, we investigated whether a component of this signature could risk stratify patients with BCa. Methods: Utilizing immunohistochemistry, we investigated angiogenin, MMP-2, p53, RB and PAI-1 expression from 939 patients with BCa. The expression levels were scored by assigning a proportion score and an intensity score to yield a total staining score for each protein...
November 21, 2017: Oncotarget
Bum Sik Tae, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Kyung Chul Moon, Ja Hyeon Ku
The prognostic value of repeat transurethral resection of bladder tumor (TURBT) in patients with diagnosed high-risk, non-muscle-invasive bladder cancer (NMIBC) was investigated. We retrospectively reviewed the medical records of patients treated from October 2004 to December 2013 at Seoul National University who underwent repeated TURBT within 2-6 weeks after an initial resection. The study enrolled patients who had been diagnosed with NMIBC at both the initial and repeat TURBT; patients with muscle-invasive tumors on repeat TURBT were excluded...
2017: PloS One
Linfeng Zheng, Kaiyan Chen, Liang Zhu, Dan Su, Guoping Cheng
The DOC-2/DAB2 interactive protein (DAB2IP) is a novel member of the Ras GTPase-activating protein family, and its downregulation is an unfavorable prognostic factor in several human malignancies. In this study, we retrospectively analyzed clinicopathological features, outcomes, and DAB2IP expression in 77 patients with urothelial carcinoma of the bladder (UCB). Expression of DAB2IP and p-STAT3 was examined in tumors and in matched adjacent non-cancerous tissues, using immunohistochemistry. We found a marked reduction in the expression of DAB2IP in UCB specimens, which was significantly associated with advanced pathological stage (P=0...
2017: OncoTargets and Therapy
Kouzaburou Tanuma, Koji Kawai, Haruki Tsuchiya, Yoshitaka Matsumoto, Shuya Kandori, Takahiro Kojima, Tomokazu Kimura, Akira Joraku, Jun Miyazaki, Hiroyuki Nishiyama, Akiko Sakata
A 68-year-old Japanese man was referred to Tsukuba University Hospital for bladder cancer treatment. He had undergone a transurethral resection of a bladder tumor (TURBT) at a local hospital, but the pathological specimen did not contain muscle layer. Abdominal computed tomography (CT) and magnetic resonance imaging revealed a 3 cm non-papillary bladder tumor with muscle invasion, but there was no apparent calcification. The patient underwent re-TURBT at our hospital for diagnosis and staging. A non-papillary pedunculated tumor was identified in the bladder dome, and it contained a small papillary part...
November 2017: Hinyokika Kiyo. Acta Urologica Japonica
Sho Minami, Kazumasa Matsumoto, Ryo Nagashio, Daisuke Hagiuda, Eriko Fukuda, Naoki Goshima, Manabu Hattori, Benio Tsuchiya, Kazuo Hachimura, Shi-Xu Jiang, Makoto Saegusa, Masatsugu Iwamura, Yuichi Sato
BACKGROUND/AIM: Bladder cancer (BC) has a high recurrence rate and may progress to being a muscle-invasive lesion, that is potentially associated with a poor prognosis. We identified tumor-associated proteins that were recognized by autoantibodies in sera from patients with high-grade non-muscle-invasive bladder cancer (HG-NMIBC) by proteomic analysis. MATERIALS AND METHODS: The serum levels of these autoantibodies against identified proteins were validated by dot blot analysis with sera from 95 patients with BC and 35 healthy controls...
December 2017: Anticancer Research
Sophie Mc Adam, Laurent Derré, Patrice Jichlinski, Ilaria Lucca
The treatment of urothelial bladder cancer has changed very little in recent years, with high rates of disease recurrence and progression, even in low aggressive urothelial bladder cancer. Immunotherapy has already proven its effectiveness as a treatment for several types of cancer and has been used in high-grade non-muscle-invasive bladder cancer for decades. Recent findings on immune checkpoints inhibitors have opened up a new chapter for treatment of bladder cancer, offering interesting therapeutic perspectives that could revolutionize the management...
November 29, 2017: Revue Médicale Suisse
Foteini D Tsikrika, Margaritis Avgeris, Panagiotis K Levis, Theodoros Tokas, Konstantinos Stravodimos, Andreas Scorilas
Clinical heterogeneity of bladder cancer prognosis requires the identification of bladder tumors' molecular profile to improve the prediction value of the established and clinically used markers. In this study, we have analyzed miR-221/222 cluster expression in bladder tumors and its clinical significance for patients' prognosis and disease outcome. The study included 387 tissue specimens. Following extraction, total RNA was polyadenylated at 3'-end and reversed transcribed. SYBR-Green based qPCR assays were performed for the quantification of miR-221/222 expression...
March 2018: Genes, Chromosomes & Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"